Stemedica Cell Technologies, Inc. ("Stemedica") is a specialty biopharmaceutical company that develops and manufactures innovative, best-in-class adult stem cell products. Stemedica also certifies and licenses highly-accredited Hospitals and Treatment Centers where patients are treated with Stemedica's proprietary stem cell technology and patented transplantation procedures.

Founded by Maynard Howe, PhD, Nikolai Tankovich, MD, and Roger Howe, PhD, Stemedica was formed as a response to a personal family tragedy. To achieve their vision of saving, restoring and enhancing quality of life, the leaders at Stemedica acquired the intellectual property rights to several stem cell technologies and then invested in the enhancement of those technologies by recruiting a diverse team of highly-trained and respected research, medical and technology development professionals.

Stemedica utilizes proprietary and patented technology derived from over 30 years of research and innovation in Russia and other parts of Europe. Stemedica is a forged collaboration between three decades of successful adult stem cell therapies and the business development and leadership skills that Stemedica has assembled.

The Company’s technology, products, protocols and support services provide Stemedica with distinct and tangible advantages. Stemedica:

• Successfully acquired, transferred, commercialized and advanced thirty years of research and human treatment experience in stem cells
• Provides “no option” patients with access to advanced treatment today at Stemedica accredited Licensed Treatment Centers
• Uses proprietary processes and procedures for the isolation, preparation and production of multiple adult stem cell lines
• Utilizes multiple cell technology formulated and customized for disease-specific conditions
• Deploys treatment protocols designed to address complex patient-specific, medical conditions
• Maintains strategic relationships with leading hospitals, academic institutions, research and non profit organizations
• Strictly adheres to all United States and International regulatory guidelines for its pre-clinical and clinical studies

Most competitive product offerings today only offer a single cell, “one size fits all”, single transplantation process. Stemedica believes the Company’s dynamic, highly-customized approach to treating complex diseases creates a significant point-of-difference for Stemedica and the Company’s product offerings.

Because of the potential superiority of efficacy and treatment results, over time, the Company seeks to have its stem cell products become, ‘The Products of Choice’ for discerning physicians, patients and Treatment Centers worldwide. This is the same model that Intel successfully used with its ‘Intel Inside’ strategy.

Stemedica is also pro-active in utilizing supplemental treatment applications as part of the StemedicaCSP™ activation process. Supplemental treatment applications include the use of pharmaceutical products and medical devices such as lasers and other implantable devices.

Stemedica's leadership team brings a wide array of significant accomplishments in their respective fields to bear on the company's overall growth and development. Two of the company's executives, Drs. Maynard and Roger Howe have a long track record of successful business and product development. Their founding partner, Dr. Nikolai Tankovich, is world-renowned for his development of medically-based break though technology. Together, they form the senior-most leadership of the company.

This leadership team has assembled some of the world's leading adult stem cell and business experts to further the advancement of adult stem cell therapies in the field of regenerative medicine. The team applies purpose-driven scientific, medical, and strategic business thinking to all their activities. The company operates with the highest standards of compliance and professionalism and focuses on corporate and social responsibility as key to their business.

As part of its commitment to advancing regenerative medicine, Stemedica partners with leading scientists and academic institutions from around the world. The goal of Stemedica’s work with each of these strategic partners is to develop, introduce, and otherwise advance processes and methodologies for viable extraction, processing, and transplantation of adult stem cells.

Stemedica's strategic partners and collaborators include physicians and researchers from Stanford University, the Burnham Institute for Medical Research, Beckman Laser Institute, Université de Lausanne, Fedorov Eye Institute and Hospital for Microsurgery and the Koltsov Institute of Developmental Biology, among many others.

Stemedica's operations include patented and proprietary adult stem cell technologies. Stemedica uses only adult stem cells in their manufacturing processes. Stemedica's stem cell products and services incorporate all current good practices standards (cGMP, cGLP, cGTP). They also follow FDA guidelines or those of the regulatory agencies in the countries of manufacture and where Licensed Treatment Centers are located. Stemedica maintains a singular focus on compliance, efficacy and biosafety throughout its manufacturing and distribution processes.

In addition to jointly identifying and introducing new options for treating diseases and developing new therapeutic strategies using adult stem cells, Stemedica expects to become "tissue independent" in the near future. Being "tissue independent" enables Stemedica to manufacture their adult stem cell products solely from adult stem cell Master Cell Banks. These banks will store reserves of adult stems cells ready to be deployed for use in patient therapy through worldwide Licensed Treatment Centers.

Treatments using Stemedica's propriety adult stem cell technology transplantation protocols are administered through Licensed Treatment Centers located around the world. These Centers must pass a rigorous screening process and comply with specific guidelines in order to be licensed by Stemedica. Centers offer patient treatment therapies for stroke, Alzheimer's, Parkinson's, ischemic head trauma, spinal cord injury, diseases of the eye such as age-related macular degeneration and diabetic retinopathy as well as skin, scar and bone regeneraton.